(1th Nov 2013) Mr. David Dally appointed Chief Executive Officer of MerLion Pharmaceuticals

 
 

Mr. David Dally appointed Chief Executive Officer of MerLion Pharmaceuticals

 
Singapore, 1st November 2013 - MerLion Pharmaceuticals (“MerLion”) announced today the appointment of Mr David Dally as Chief Executive Officer (“CEO”).

Mr Dally has been Chief Financial Officer of MerLion since February 2007. He has over 20 years’ financial and commercial experience in the bio-medical industry, including senior roles with KuDOS Pharmaceuticals Ltd and at Amersham plc.

Mr Jean-Philippe Tripet, Chairman of the Board of MerLion said “I am pleased that David Dally, who has been a member of the senior management team for several years, is taking over the CEO position.  David will focus on developing strategic opportunities with both the systemic and topical formulations available within MerLion’s finafloxacin program.  I wish to thank Dr Tony Buss for his many years of service and for the significant contribution he has made to MerLion”.

Mr. Dally added, “The past 12 months have seen a number of significant clinical milestones for finafloxacin. I look forward to continuing to build on this momentum in the coming months as we work to advance our drug candidate rapidly as a solution for many serious bacterial infections”.

About Finafloxacin

Finafloxacin is a highly differentiated antibacterial candidate that is being developed as a potential first-line treatment for serious bacterial infections primarily in hospital settings and in topical applications.

Finafloxacin has an outstanding safety profile and exhibits an all-inclusive spectrum of activity that covers Gram-positive, Gram-negative, anaerobic and atypical pathogens. The compound displays rapid bactericidal activity against slowly growing and surface attached bacteria in biofilms and in contrast to classical fluoroquinolones, its antibacterial activity is enhanced in the acidified environments found at most infection sites e.g. urine, abscesses, deep seated wounds, chronically infected tissues and stomach mucosa.

A Phase II trial is currently underway in Europe to test the efficacy of finafloxacin as a short iv course, high dose regimen with an oral step-down option for the treatment of cUTI and pyelonephritis and is expected to be completed in early 2014.

To date, finafloxacin has been studied in nearly 1,000 human subjects; two Phase III trials with a topical formulation have been successfully completed in addition to successful Phase IIa studies (treatment of uncomplicated UTI and eradication of Helicobacter pylori) and Phase I studies with oral and iv formulations of finafloxacin.

In July 2013 finafloxacin was granted QIDP and FDA Fast Track status for three important therapeutic indications; cUTI/pyelonephritis, cIAI and ABSSSI.  QIDP designation is provided under the Generating Antibiotic Incentives Now (“GAIN”) Act, established in 2012 in the USA to provide incentives for the development of new treatments for serious or life-threatening infections.

About MerLion Pharmaceuticals

MerLion Pharmaceuticals Pte Ltd is a privately held company headquartered in Singapore with clinical development operations based in Berlin, Germany. The company is focused on developing its lead antibacterial candidate, finafloxacin, through early and mid-stage clinical trials. MerLion is supported by a group of leading global investors including Aravis, Bio*One Capital,a subsidiary of EDBI, HeidelbergCapital and Nomura Research & Advisory.

For more information visit MerLion’s website http://www.merlionpharma.com

MerLion Contact:
David Dally, CEO

Tel:
+65 6829 5600
 

E-mail: enquiry@merlionpharma.com